WO2000010562A8 - Physically stable and x-ray amorphous form of hydrochloride ranitidine having an increased anti-ulcer activity and method for producing the same - Google Patents

Physically stable and x-ray amorphous form of hydrochloride ranitidine having an increased anti-ulcer activity and method for producing the same

Info

Publication number
WO2000010562A8
WO2000010562A8 PCT/RU1998/000269 RU9800269W WO0010562A8 WO 2000010562 A8 WO2000010562 A8 WO 2000010562A8 RU 9800269 W RU9800269 W RU 9800269W WO 0010562 A8 WO0010562 A8 WO 0010562A8
Authority
WO
WIPO (PCT)
Prior art keywords
ray amorphous
producing
amorphous form
physically stable
same
Prior art date
Application number
PCT/RU1998/000269
Other languages
French (fr)
Russian (ru)
Other versions
WO2000010562A1 (en
Inventor
Nikolai Borisovich Leonidov
Svetlana Igorevna Uspenskaya
Alexandr Borisovi Krasnokutsky
Original Assignee
Leonidov Nikolai B
Svetlana Igorevna Uspenskaya
Alexandr Borisovi Krasnokutsky
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leonidov Nikolai B, Svetlana Igorevna Uspenskaya, Alexandr Borisovi Krasnokutsky filed Critical Leonidov Nikolai B
Priority to AU15136/99A priority Critical patent/AU1513699A/en
Priority to RU2001105137/15K priority patent/RU2385155C2/en
Priority to PCT/RU1998/000269 priority patent/WO2000010562A1/en
Priority to RU2001105137/14A priority patent/RU2203048C2/en
Publication of WO2000010562A1 publication Critical patent/WO2000010562A1/en
Publication of WO2000010562A8 publication Critical patent/WO2000010562A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Abstract

The present invention relates to a new and formerly known form of hydrochloride ranitidine having H2-blocking properties. This form is X-ray amorphous, substantially differs from the formerly known crystalline modifications due to its characteristics, and also exhibits an enhanced anti-ulcer effect. This X-ray amorphous form is physically stable and can be used in medicine. This invention also relates to a method for producing this X-ray amorphous form from formerly known crystalline modifications.
PCT/RU1998/000269 1998-08-18 1998-08-18 Physically stable and x-ray amorphous form of hydrochloride ranitidine having an increased anti-ulcer activity and method for producing the same WO2000010562A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU15136/99A AU1513699A (en) 1998-08-18 1998-08-18 Physically stable and x-ray amorphous form of hydrochloride ranitidine having anincreased antitumoral activity and method for producing the same
RU2001105137/15K RU2385155C2 (en) 1998-08-18 1998-08-18 Physically stable x-ray amorphous form of ranitidine hydrochloride with improved antiulcer activity and method for preparing thereof
PCT/RU1998/000269 WO2000010562A1 (en) 1998-08-18 1998-08-18 Physically stable and x-ray amorphous form of hydrochloride ranitidine having an increased anti-ulcer activity and method for producing the same
RU2001105137/14A RU2203048C2 (en) 1998-08-18 1998-08-18 Physically stable roentgen-amorphous form of ranitidine hydrochloride with enhanced antiulcer activity and method for its preparing

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/RU1998/000269 WO2000010562A1 (en) 1998-08-18 1998-08-18 Physically stable and x-ray amorphous form of hydrochloride ranitidine having an increased anti-ulcer activity and method for producing the same

Publications (2)

Publication Number Publication Date
WO2000010562A1 WO2000010562A1 (en) 2000-03-02
WO2000010562A8 true WO2000010562A8 (en) 2001-03-15

Family

ID=20130252

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU1998/000269 WO2000010562A1 (en) 1998-08-18 1998-08-18 Physically stable and x-ray amorphous form of hydrochloride ranitidine having an increased anti-ulcer activity and method for producing the same

Country Status (3)

Country Link
AU (1) AU1513699A (en)
RU (2) RU2385155C2 (en)
WO (1) WO2000010562A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019875D0 (en) * 1990-09-11 1990-10-24 Glaxo Group Ltd Pharmaceutical compositions
EP0687174B1 (en) * 1993-03-05 2001-06-13 Hexal Ag Crystalline cyclodextrin inclusion complexes of ranitidine hydrochloride and process for their preparation
DE9420259U1 (en) * 1994-12-17 1995-02-09 Roehm Gmbh Debittered ranitidine preparation

Also Published As

Publication number Publication date
RU2203048C2 (en) 2003-04-27
AU1513699A (en) 2000-03-14
WO2000010562A1 (en) 2000-03-02
RU2385155C2 (en) 2010-03-27

Similar Documents

Publication Publication Date Title
AU2001290295A1 (en) Crystalline mww-type titanosilicate , its preparation and use thereof for producing epoxides
HUP0100531A3 (en) Crystalline base of citalopram, method for producing it and medicament containing the same
AU6198700A (en) Process for producing phenyl-alkanes compositions produced therefrom, and uses thereof
AU586318B2 (en) Crystalline, anhydrous ```-form of 2-``4-(2-furoyl)- (2-piperazin)-1-yl``-4-amino-6, 7-dimethoxyquinazoline hydrochloride and a process for its preparation
WO2000016762A3 (en) Method for reducing nicotine dependency
HUP0204170A3 (en) 5-thia-omega-substituted phenyl-prostaglandin e derivatives, process for producing the same and drugs containing the same as the active ingredient
AU2002213977A1 (en) Novel anticholinergics, method for the production thereof and use thereof as medicaments
HUP9801599A3 (en) Use of imidazolin derivatives having alfa1l agonist effect for producing pharmaceutical compositions for treatment of incontinence, novel imidazolin derivatives and process for producing them
WO2001010816A3 (en) Substituted 2-dialkylaminoalkylbiphenyl derivatives
AU7961200A (en) Urea derivative, process for producing the same, and medicine containing the urea derivative
WO2001087831A3 (en) Novel amorphous form of omeprazole salts
AU4600200A (en) Salts of 2,2-dimethyl-1,3-dioxane intermediates and process for the preparation thereof
HUP0101482A3 (en) Piperidinyl and n-amidinopiperidinyl derivatives, use of them for producing pharmaceutical compositions and pharmaceutical compositions containing the same
HUP9602640A3 (en) Substituted benzoyl-guanidine derivatives, process for producing them, pharmaceutical compositions containing them and the use of the compds.
WO2000010562A8 (en) Physically stable and x-ray amorphous form of hydrochloride ranitidine having an increased anti-ulcer activity and method for producing the same
AU5160599A (en) Method for the production of n,n'-carbonyl diazoles
EP1059304A4 (en) Novel polysaccharide derivatives, process for the production thereof and medicinal compositions containing the same as the active ingredient
AU2910900A (en) Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ols, method for producing them and their use as medicaments
WO2002011668A3 (en) 5'-deoxy-n-(substituted oxycarbonyl)-5-fluorocytosine and derivatives thereof, method of preparing same, and anticancer composition comprising same as active ingredients
AU6867600A (en) Drink comprising helianthus tuberosus as the main component and process for producing the same
AU2001277801A1 (en) Process for preparing 2,3-diaminopropanols and synthesis of other compounds using 2,3-diaminopropanols
AU2001284476A1 (en) Novel crystals of 1,3,4-oxadiazole derivative, process for producing the crystals and medicines containing the same as the active ingredient
AU1397800A (en) Method of producing paroxetine hydrochloride
HUP9900263A3 (en) 11-acetyl-12,13-dioxabicyclo[8.2.1.]tridecenon derivatives, process for producing them and pharmaceutical compositions containing them
HK1049485A1 (en) DithiepinoÄ6,5-BÜpyridines, and related compositions, methods of producing and uses.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR CA CN CZ HU IL JP RU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C1

Designated state(s): AU BR CA CN CZ HU IL JP RU US

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

CFP Corrected version of a pamphlet front page

Free format text: TITLE PUBLISHED IN ENGLISH LANGUAGE REPLACED BY CORRECTED TITLE

AK Designated states

Kind code of ref document: B8

Designated state(s): AU BR CA CN CZ HU IL JP RU US

AL Designated countries for regional patents

Kind code of ref document: B8

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

CFP Corrected version of a pamphlet front page

Free format text: UNDER (54) PUBLISHED TITLE IN ENGLISH REPLACED BY CORRECT TITLE AND UNDER (57) PUBLISHED ABSTRACT IN ENGLISH REPLACED BY CORRECT ABSTRACT

122 Ep: pct application non-entry in european phase